Interview with Aihua Pan, Chairman, SinoBioway Group
Could you provide us with an introduction to the company and an overview of operations from the company’s founding through to your position today as a leading biotech company in…
Address: PKU Biocity No. 39 ShangDiXi Lu, Haidian, Beijing, P.R. China
Tel: 86 10 8289 0924
SinoBioway Group Co., Ltd. was founded in 1992 and is one of the three major industry groups of Beijing University. It is mainly engaged in bio-industry development and the establishment of bio-economic systems with a focus on investment in three main areas: bio-medicine, bio-agriculture and bio-services. After more than ten years of dedication, the group has become China’s most influential and modern bio-enterprise.
The group now owns three main facilities: Beijing University Biological City, Beijing University Biological Park at Xiamen and Guangzhou Liuxi Biological Bay. Additionally, the group operates multiple holding subsidiaries such as Beijing Sinovac Biotech Co., Ltd., Xiamen Bioway-PKU Biotech Co., Ltd., Guangzhou Weiming Biotech Co., Ltd., Weiming Nature Unity Chinese Medicine Co., Ltd. and Beijing Weiming Kaituo Agricultural Biotech Ltd.
The main products of SinoBioway include an injection of mouse-nerve growth factor (Nobex ®), an inactivated hepatitis A vaccine (Healive ®), a hepatitis B vaccine (Bilive ®), anti-flu vaccines (Anflu ®, Panflu ®, and Panflu.1 ®), as well as hundreds of kinds of Chinese medicinal granules. The group now has established a fairly complete R & D system with centers for: Bio-Pharmaceutical Research, Vaccine Research, National Crop Molecular Design, Bio-Intelligence Research, Bio-Economic Research. It operates various institutions and R & D platforms while employing a group of outstanding research personnel.
Having researched mainly for the bio-economy, biological drugs (generic drugs and peptide drugs), human vaccines, modern Chinese medicine, molecular crop breeding, biomass energy and bio-intelligence technology, the group has achieved a series of major breakthroughs. These include the successful development and production of the world’s first drug treatment of traumatic nerve injury – the “nerve growth factor”, the world’s first “inactivated vaccine targeting SARS virus”, and China’s first “human-use influenza vaccine”. The world’s first influenza A (H1N1) vaccine -Panflu.1 ® was successfully produced on September 3, 2009. The group has initiated the world’s first “bio-economy incubator” (an efficient R & D system of new drugs), established a theoretical system of bio-economy, created an economic bio-restructuring model, and carried out a preliminary study of bio-industry development ideas suitable for China’s national conditions.
SinoBioway has engaged in corporate restructuring and through government guidance has shifted to a market approach. At the moment, the group has formed five industry groups on the basis of existing enterprises which include: vaccines, traditional Chinese medicine, bio-pharmaceuticals, modern agriculture and biological services. Through forming bio-economic systems in the industrial, R & D and financial arena, the group aims to build SinoBioway into a flagship company for the bio-economy era.
vaccines, traditional Chinese medicine, bio-pharmaceuticals
Could you provide us with an introduction to the company and an overview of operations from the company’s founding through to your position today as a leading biotech company in…
Servier was one of the first pharmaceutical companies to establish a presence in China back in 1979. How has Servier’s presence evolved alongside China’s huge transformations of the last decades?…
In 2012 Servier China became the 3rd largest affiliate within the Servier group. How has the company progressed since then? Servier-China is a linchpin for Servier. Servier-China has become the…
Since this interview, Michael Ryde has left Lundbeck China and is now working as Commercial Counsellor, Teamleader Health, at the Danish Embassy in Beijing. Oscar Parra currently holds the position…
Could you provide us with an introduction to the company and an overview of operations from the company’s founding through to your position today as a leading biotech company in…
You began your career at Pfizer, working your way up the organizational ladder, when suddenly you decided to come to China back in 2001, well before China was on the…
This interview was conducted with Christopher Stephens, managing partner of Orrick, Herrington & Sutcliffe’s Asia offices with supporting responses from Xiang Wang, lead partner of the firm’s IP pracitce as…
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
First, let me briefly introduce myself. I used to work in Fuxin, a small city in the industrially advanced province of Liaoning which is equivalent to a state in the…
Please introduce to our readers the general situation and driving force behind the creation of the Beijing Pharma and Biotech Center and its core mandate? Established in 1996, BPBC is…
You have an MD and you’ve worked in industry, but then you decided to become and entrepreneur. What challenges did you face in transitioning to starting your own company and…
Finnegan is a leader and expert on the topic of intellectual property and it entered Asia in the late 1980s with an office in Tokyo yet China only very recently.…
You started the Chinese operations and have been working in the country for many years but recently moved up to running all operations in Asia Pacific. Are you still closely…
See our Cookie Privacy Policy Here
